@article{2e6371ec98fe470bae5121afda711ba9,
title = "Lessons Learned in Best Practice Infertility Treatment",
author = "Beilby, \{Kiri H.\}",
note = "Funding Information: A lot of this might come down to the unknown unknowns of assisted reproduction. With an estimated 40\% of infertilities idiopathic, and 70–80\% of treatments unsuccessful in producing a live birth, there lies a large and unexplained grey area of {\textquoteleft}hope{\textquoteright} whereby both clinician and patient want to create opportunity for success. With much of the industry privately funded, within a free market, consumer autonomy is supported by commercialised business, both by medical device companies selling treatments and by clinics trying to offer competitive advantage. Regulatory bodies such as the HFEA in the UK have tried to support consumer decision making by setting up a traffic light system to expose the evidence-based nature of add-ons (none receiving a green light), and time will tell how much of a success this is. Historically, the biggest shift in infertility treatment practice has been from multiple to single embryo transfer (SET) and was driven financially through the subsidised treatment of SET, and later by data-driven example, reducing the complications resulting from pregnancies with",
year = "2022",
month = jul,
doi = "10.31083/j.ceog4907164",
language = "English",
volume = "49",
journal = "Clinical and Experimental Obstetrics and Gynecology",
issn = "0390-6663",
publisher = "IMR Press",
number = "7",
}